Haohai Biotech (A19112): Leading biomaterials company has multiple core technologies
Leading company in biomaterials, with multiple products ranking first in the country.
Founded in 2007, the company is a scientific and technological innovative enterprise that applies biomedical material technology and genetic engineering technology to the development, production and sales of medical devices and drugs.
The company’s main products include intraocular lenses, ophthalmic viscoelastic agents, hyaluronic acid, regenerative human epidermal growth factor, and medical chitin.
At present, the company has completed the industrial reorganization of absorbable biomedical materials represented by hyaluronic acid and medical chitosan, and realized the industrialization of human epidermal growth factor, an innovative genetically engineered drug.
The company is the largest manufacturer of ophthalmic viscoelastic agents, joint cavity viscoelastic supplements, and surgical anti-adhesive agents. It is the second largest domestic manufacturer of regenerative human epidermal growth factor for external use. The company’s hyaluronic acid products “Haiwei” and “Guerlain” areWell-known brand of domestic hyaluronic acid skin fillers; the company’s sales of artificial lens products account for about the Chinese market share, optoelectronic materials have been recognized by China, the United States, the United Kingdom and other 70 countries worldwide.
Jiang Wei and You Jie jointly hold the company 49.
81% of the shares are the actual controllers of the company.
The performance has grown rapidly, and the gross profit margin is at a relatively high 武汉夜网论坛 level.
The company’s operating income for 2016-2018 was 8.
54 and 15.
5.8 billion yuan, net profit attributable to mothers was 3.
15 ppm; net cash flows from operating activities were 2.
5.1 billion, 3.
91 ppm; gross margins were 83.
51%; R & D expenses accounted for 5 of the revenue.
As a result of the merger, the merger and acquisition of the company was completed, the income increased accordingly.
The company’s products have high technical barriers and gross profit margins have remained relatively high for a long time.
Independent innovation + outsourcing acquisition integration, master a variety of leading technologies, it is planned to raise funds to support research and development and expand production capacity.
Since its establishment, the company has carried out a series of acquisitions and integrations around the world on the basis of independent research and development.
Intraocular lens products, the core consumables of cataract surgery: The company’s products cover a full range of products from PMMA rigid intraocular lenses to high-end foldable functional intraocular lenses.
The company’s “development of new intraocular lenses and high-end ophthalmic implant materials” was successfully selected into the “13th Five-Year Plan” national key plan.
In addition, the company’s subsidiary Contamac is one of the world’s largest independent opto-optic materials manufacturers, leading the global market share.
In terms of medical chitin: the company ‘s winner, medical chitin, is the first in the country and is the first internationally successful medical chitin product in the human body; in terms of hyaluronic acid: the company also masters the “cockscomb extraction method” and”Bacterial fermentation method” is two mainstream processes. It is one of the few companies in China that has obtained the approval of the sodium hyaluronate raw material Chinese medicine standard; in terms of recombinant human epidermal growth factor: the company uses genetic engineering technology to develop recombinant human epidermisGrowth factor is the first internationally approved product of this type and has won the National Science and Technology Progress Award.
The company plans to raise funds 14.
8.4 billion US dollars, mainly to strengthen the research and development of new products and expand the production capacity of hyaluronic acid, medical chitin, external human epidermal growth factor and other products.
Meet the first set of listing standards for science and technology board.
The company’s net profit attributable to the parent in 2017 and 2018 were 3 respectively.
7.2 billion and 4.
US $ 1.5 billion, with an estimated market value of not less than US $ 1 billion.The company complies with the listing standards of “expected market value of not less than RMB 100,000, net profit gradually moving forward and net profit of not less than RMB 50 million in the past two years”.
Risk Warning: Product Restructuring Risk, Policy Risk, Overseas Operating Risk